PL2393520T3 - Obróbka strukturyzowanych peptydów - Google Patents

Obróbka strukturyzowanych peptydów

Info

Publication number
PL2393520T3
PL2393520T3 PL10704902T PL10704902T PL2393520T3 PL 2393520 T3 PL2393520 T3 PL 2393520T3 PL 10704902 T PL10704902 T PL 10704902T PL 10704902 T PL10704902 T PL 10704902T PL 2393520 T3 PL2393520 T3 PL 2393520T3
Authority
PL
Poland
Prior art keywords
peptide processing
structured peptide
structured
processing
peptide
Prior art date
Application number
PL10704902T
Other languages
English (en)
Inventor
Gregory Paul Winter
Christian Heinis
Elise Bernard
David Loakes
Marina Vaysburd
Original Assignee
Bicycle Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2009/000301 external-priority patent/WO2009098450A2/en
Application filed by Bicycle Therapeutics Ltd filed Critical Bicycle Therapeutics Ltd
Publication of PL2393520T3 publication Critical patent/PL2393520T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
PL10704902T 2009-02-04 2010-02-04 Obróbka strukturyzowanych peptydów PL2393520T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2009/000301 WO2009098450A2 (en) 2008-02-05 2009-02-04 Methods and compositions
GBGB0913775.3A GB0913775D0 (en) 2009-08-06 2009-08-06 Multispecific peptides
EP10704902.5A EP2393520B1 (en) 2009-02-04 2010-02-04 Structured peptide processing
PCT/EP2010/000690 WO2010089116A1 (en) 2009-02-04 2010-02-04 Structured peptide processing

Publications (1)

Publication Number Publication Date
PL2393520T3 true PL2393520T3 (pl) 2016-01-29

Family

ID=41129757

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10704902T PL2393520T3 (pl) 2009-02-04 2010-02-04 Obróbka strukturyzowanych peptydów

Country Status (11)

Country Link
US (5) US8778844B2 (pl)
EP (3) EP2393519B1 (pl)
CN (2) CN102405059B (pl)
AU (2) AU2010211283B2 (pl)
CA (2) CA2751505C (pl)
DK (1) DK2393520T3 (pl)
ES (2) ES2551580T3 (pl)
GB (1) GB0913775D0 (pl)
PL (1) PL2393520T3 (pl)
SG (3) SG173169A1 (pl)
WO (3) WO2010089116A1 (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0914110D0 (en) * 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
EP3357511B1 (en) 2011-06-30 2020-05-13 Genzyme Corporation Inhibitors of t-cell activation
CN103906865B (zh) 2011-10-07 2017-12-08 拜斯科医疗有限公司 结构化多肽特异性的调控
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
ES2755104T3 (es) 2012-05-17 2020-04-21 Ra Pharmaceuticals Inc Inhibidores peptídicos y peptidomiméticos
US20140274759A1 (en) * 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2015009701A1 (en) 2013-07-15 2015-01-22 North Carolina State University Protease-resistant peptide ligands
RU2674604C2 (ru) * 2013-10-28 2018-12-11 БайсиклРД Лимитед Новые полипептиды
PT3215518T (pt) 2014-10-29 2021-05-25 Bicyclerd Ltd Ligantes de péptido bicíclicos específicos para mt1-mmp
CN105985524A (zh) * 2015-02-10 2016-10-05 北京师范大学 针对特定靶标具备指纹识别特征的多肽复合物分子的构建方法
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
US11458205B2 (en) 2015-08-04 2022-10-04 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
US9765117B2 (en) 2015-08-24 2017-09-19 Romek Figa Peptides for treating cancer
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
GB201600903D0 (en) * 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Peptide derivaties
AU2017278022B2 (en) * 2016-03-30 2023-07-06 Synovo Gmbh Detecting microbial infection in wounds
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
EP3467107B1 (en) * 2016-06-07 2022-06-01 Kaneka Corporation Ribosome display complex and production method therefor
RU2019110848A (ru) * 2016-09-14 2020-10-15 Дьюк Юниверсити Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств
KR20190064600A (ko) 2016-09-23 2019-06-10 듀크 유니버시티 Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
EP3544621A1 (en) 2016-11-27 2019-10-02 BicycleRD Limited Methods for treating cancer
CN110603261A (zh) 2016-12-23 2019-12-20 拜斯科阿迪有限公司 具有新型键结构的肽衍生物
EP3565638B8 (en) * 2017-01-06 2024-04-10 BicycleRD Limited Bicycle conjugate for treating cancer
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
CN110366431B (zh) 2017-02-28 2023-07-18 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
EP3661948B1 (en) * 2017-08-04 2022-06-01 BicycleTx Limited Bicyclic peptide ligands specific for cd137
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) * 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
CA3095582A1 (en) * 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
GB201808835D0 (en) * 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
KR20210020107A (ko) 2018-06-13 2021-02-23 암피스타 테라퓨틱스 엘티디 UchL5 표적화를 위한 이중작용성 분자
CA3103185A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810325D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) * 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DUAL AGONIST FUSION PROTEINS
GB201820325D0 (en) * 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
MX2021006991A (es) * 2018-12-13 2021-10-13 Bicycletx Ltd Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
BR112021022315A2 (pt) 2019-05-09 2021-12-28 Bicycletx Ltd Ligantes de peptídeo bicíclicos específicos para ox40
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
WO2021064428A1 (en) * 2019-10-03 2021-04-08 Bicycletx Limited Heterotandem bicyclic peptide complexes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
US20030166003A1 (en) * 1999-06-14 2003-09-04 Cochran Andrea G. Structured peptide scaffold for displaying turn libraries on phage
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
GB2428293A (en) * 2005-07-13 2007-01-24 Domantis Ltd Phage display libraries
EP2653543A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and Compositions

Also Published As

Publication number Publication date
SG173460A1 (en) 2011-09-29
DK2393520T3 (en) 2015-10-26
CN102405059B (zh) 2016-10-12
US8778844B2 (en) 2014-07-15
AU2010211282A1 (en) 2011-08-18
US20120101256A1 (en) 2012-04-26
CN102405060A (zh) 2012-04-04
WO2010089115A8 (en) 2011-12-22
CA2751505C (en) 2019-08-20
US20160046928A1 (en) 2016-02-18
SG173169A1 (en) 2011-09-29
US20120101253A1 (en) 2012-04-26
AU2010211283A1 (en) 2011-08-11
WO2010089117A1 (en) 2010-08-12
CN102405060B (zh) 2016-04-13
US9670482B2 (en) 2017-06-06
US20120142541A1 (en) 2012-06-07
WO2010089116A1 (en) 2010-08-12
US9644201B2 (en) 2017-05-09
EP2393518A1 (en) 2011-12-14
US20140163201A1 (en) 2014-06-12
CN102405059A (zh) 2012-04-04
CA2750969C (en) 2019-05-07
ES2896398T3 (es) 2022-02-24
EP2393519A1 (en) 2011-12-14
EP2393520B1 (en) 2015-07-15
EP2393520A1 (en) 2011-12-14
AU2010211283B2 (en) 2015-12-10
ES2551580T3 (es) 2015-11-20
CA2750969A1 (en) 2010-08-12
EP2393518B1 (en) 2021-08-04
CA2751505A1 (en) 2010-08-12
GB0913775D0 (en) 2009-09-16
AU2010211282B2 (en) 2016-02-11
EP2393519B1 (en) 2018-01-03
WO2010089115A1 (en) 2010-08-12
US8685890B2 (en) 2014-04-01
SG10201503705UA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
SG10201503705UA (en) Structured Peptide Processing
HK1249580A1 (zh) 使用納米造孔儀的蛋白質檢測
HK1218558A1 (zh) 蛋白
EP2507756A4 (en) TREATMENT OF VALUABLE ITEMS
GB0914110D0 (en) Peptide libraries
EP2415015A4 (en) BAR CODE PROCESSING
ZA201105852B (en) Antibiotic peptides
EP2437770A4 (en) ANTIMICROBIAL PEPTIDES
EP2431464A4 (en) APTAMERE RECOGNIZING A PEPTIDE
GB0921986D0 (en) Video processing
EP2480578A4 (en) MODIFICATION OF POLYPEPTIDE
HRP20190262T1 (hr) Antimikrobni peptidi bazirani na cmap27
GB0803238D0 (en) Parallel processing
EP2417629A4 (en) SEMICONDUCTOR PROCESSING
GB2488454B (en) Multi-granular stream processing
GB0921995D0 (en) Antimicrobial peptides
EP2435468A4 (en) PEPTIDE OF FIBROMODULIN
GB0908435D0 (en) Processes
ZA201109283B (en) Protein
HK1173358A1 (en) Fviii-derived peptides fviii
GB0915710D0 (en) Processing line
GB0812665D0 (en) Interrupt processing
ZA201203722B (en) Peptide
EP2411406A4 (en) ISOFORM OF THE PEPTIDE NELL-1
EP2439209A4 (en) PEPTIDES BASED ON ENDOKININS C / D